AMENDMENT NO. 2 TO OPEN MARKET SALE AGREEMENT December 23, 2022Open Market Sale Agreement • December 23rd, 2022 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances)
This Amendment No. 2 (“Amendment No. 2”) amends that certain Open Market Sale AgreementSM, dated as of August 5, 2020, as amended by Amendment No. 1 (“Amendment No. 1”) to Open Market Sale AgreementSM, dated as of May 5, 2021 (the “Agreement”), by and between Sangamo Therapeutics, Inc. (the “Company”) and Jefferies LLC, as sales agent and/or principal (the “Agent”). Defined terms used herein and not otherwise defined shall have the meaning assigned to such terms in the Agreement.
